Jul 2 2013
Glide Pharma today announced that it has entered an agreement with global device manufacturer Nypro Healthcare to complete the design optimisation of its solid dose injector in preparation for production scale up. The company's delivery system, the Glide SDI®, is a unique technology for injecting drugs and vaccines in a solid dosage form without the need for a needle. The Glide SDI® comprises a novel tiny solid dosage, which is pushed into the skin with a small, hand-held, spring-powered device. Nypro Healthcare will work with Glide Pharma to ensure the design of the device and its components are optimised for manufacturing scale up and to ensure patient requirements, including self-administration, are met.
"This agreement marks a milestone for our Glide SDI® device as it will enable us to complete the final phase of development prior to production scale up. As a recognized leader in the development and manufacturing of precision devices we believe that Nypro Healthcare is the perfect partner to work with Glide Pharma on advancing our novel delivery system," stated Dr Mark Carnegie-Brown, CEO, Glide Pharma.
"The Glide SDI® is a highly innovative delivery system, which is very different from other technologies currently on the market. Nypro Healthcare is delighted to have been selected as Glide Pharma's partner to help progress the development of this exciting new technology," commented Chris Nother, VP Business Development, Nypro Healthcare.
Non-Hispanic Black children and low-income youth disadvantaged in concussion care